Giovanni Alessandro Buonaccorsi1, Caleb
Roberts1, James O Connor1, Chris Rose1, Sue
Cheung1, Yvonne Watson1, Karen Davies1, Lynn
Hope2, Alan Jackson1, Gordon Jayson2, Geoff
Parker3
1Imaging Science and Biomedical
Engineering, University of Manchester, Manchester , United Kingdom; 2Cancer
Research UK Dept of Medical Oncology, Christie Hospital, Manchester, United
Kingdom; 3Imaging Science and Biomedical Engineering, University
of Manchester, Manchester, United Kingdom
Using
DCE-MRI data from four patients enrolled in a trial of a VEGF inhibitor, we
performed cross-visit tumour sub-segmentations to obtain cluster volumes and
localised cluster VOI statistics for Ktrans.
In each tumour a subset of clusters showed statistically significant
post-treatment volume changes for at least one visit. Eight of 9 clusters with decreased volume
had mean Ktrans > 0.127 min-1.
Reduced post-treatment volume in clusters with high Ktrans is
consistent with reduced volume of actively-angiogenic tumour regions, as
would be expected with a VEGF inhibitor.
These effects would not be evident when using whole tumour VOI
statistics.